Relieving Chronic Itch: Oral Medication (CIPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02909569|
Recruitment Status : Withdrawn (Contract could not be agreed on.)
First Posted : September 21, 2016
Last Update Posted : May 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Pruritis||Drug: INCB039110||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Relieving Chronic Itch : Oral Medication|
|Estimated Study Start Date :||August 2018|
|Actual Primary Completion Date :||October 9, 2018|
|Actual Study Completion Date :||October 9, 2018|
INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
- Numerical Rating Scale (NRS) itch score [ Time Frame: Baseline to 12 weeks ]Absolute change from Baseline NRS itch score to week 12
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02909569
|Principal Investigator:||Brian Kim, MD/MTR||Washington University School of Medicine|